Exact sciences corporation stock.

06-Nov-2020 ... K&L Gates also counseled Exact Sciences in a common stock sale of more than eight million shares, resulting in approximately USD $869.2 million ...

Exact sciences corporation stock. Things To Know About Exact sciences corporation stock.

MADISON, Wis., August 1, 2023 -- Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company generated revenue of $622.1 million for the second quarter ended June 30, 2023, compared to $521.6 million for the same period of 2022.Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced it will present new data supporting the company's research in early cancer ...Find the latest Exact Sciences Corporation (EXK.F) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock Information; Financial Information. SEC Filings; Quarterly Results; Analyst Coverage; Interactive Analyst Center; Email Alerts; Contact UsExact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73. Today ||| 52-Week Range. 100.77.

Exact Sciences (EXAS) delivered earnings and revenue surprises of 46.84% and 11.06%, respectively, for the quarter ended March 2023. ... is selling $2 billion of stock in Las Vegas Sands Corp. so ...Dec 1, 2023 · Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal ...

Dec 1, 2023 · Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The Company is focusing its research and development efforts on three main areas: Colorectal ...

In my May 2022 article on Exact Sciences Corporation (NASDAQ:EXAS), titled "Exact Sciences Won't Likely Escape Consolidation in the Industry," I pointed out the need for the company to turn its ...The stock of Exact Sciences Corp. (EXAS) has gone down by -0.12% for the week, with a 10.16% rise in the past month and a -21.44% drop in the past quarter. The volatility ratio for the week is 3.39%, and the volatility levels for the past 30 days are 4.51% for EXAS. The simple moving average for the last 20 days is 2.04% for EXAS stock, with …MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's …Feb 23, 2023 · MADISON, Wis., Feb. 23, 2023 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated exchange and purchase agreement (the "Agreement") with a holder of certain of the Company's 0.3750% Convertible Senior Notes due 2027 (the "Existing 2027 ... Complete Exact Sciences Corp. stock information by Barron's. View real-time EXAS stock price and news, along with industry-best analysis.

The EXACT Sciences Corporation stock price gained 1.49% on the last trading day (Monday, 20th Nov 2023), rising from $66.30 to $67.29. During the last trading day the stock fluctuated 4.45% from a day low at $66.31 to a day high of $69.26. The price has been going up and down for this period, and there has been a 3.21% gain for the last …

Check out my recommendation on EXAS stock. Exact Sciences' successful BLUE-C study and potential FDA approval for the upgraded test may drive revenues. ... 2023 8:00 AM ET Exact Sciences ...

Exact Sciences Corporation's (EXAS) CEO Kevin Conroy on Q4 2020 Results - Earnings Call Transcript SA Transcripts Tue, Feb. 16, 2021 Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q3 2020 ...Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Exact Sciences Corporation‘s EXAS shares have surged 35.4% year to date against the industry’s decline of 21.2%. The Medical sector has dropped 8.1% in the said time frame. The company has a ...A high-level overview of Exact Sciences Corporation (EXAS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment …Exact Sciences Corp Stock Price History. Exact Sciences Corp’s price is currently up 3.04% so far this month. During the month of November, Exact Sciences Corp’s stock price has reached a high of $68.02 and a low of $58.43. Over the last year, Exact Sciences Corp has hit prices as high as $100.77 and as low as $40.73. Year to date, Exact ...About Exact Sciences Corp. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of the Cologuard ® and Oncotype ® tests, Exact Sciences is investing in its pipeline to develop innovative …

Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests.EXACT Sciences Corporation stock performance at a glance. Check EXACT Sciences Corporation’s past financial performance, like revenue or net income, plus the top level summary of its past and current market value. EXAS Stock Performance. USD USD; Previous close: 64: 64: Day range: 62.76 - 67.0362.76 - 67.03Year range: 43 - 100Exact Sciences Corporation (together with its subsidiaries, “Exact,” “we,” “us,” “our” or the “Company”) is a leading, global, advanced cancer diagnostics company. We have developed some of the most impactful tests in cancer diagnostics, and we are currently working to develop additional tests, with the goal ofMADISON, Wis., April 26, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $486.6 million for the first quarter ended March 31, 2022, compared to $402.1 million for the same period of 2021.Exact Sciences Corp. Presents Multiple Studies At San Antonio Breast Cancer Symposium Supporting Optimization and Individualization of Therapy for Breast Cancer Patients CI Nov. 29: Transcript : Exact Sciences Corporation Presents at The 6th Annual Evercore ISI HealthCONx Conference, Nov-29-2023 12:30 PMExact Sciences Corporation analysts consensus, targets, ratings and recommendations | Nasdaq: EXAS | Nasdaq

Historical daily share price chart and data for Exact Sciences since 2001 adjusted for splits and dividends. The latest closing stock price for Exact ...MADISON - Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that it has filed a lawsuit against Geneoscopy, Inc. in the United States District Court for the District of Delaware. The lawsuit seeks damages and a court order to stop Geneoscopy from making, using, selling, or …

The Exact Sciences Corp (NASDAQ: EXAS) stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days. Most of that value climb came yesterday, with the ...Analyst Recommendations on Exact Sciences Corporation. Goldman Sachs Adjusts Price Target on Exact Sciences to $90 From $100, Keeps Buy Rating. Nov. 03. MT. BofA Securities Cuts Price Target on Exact Sciences to $88 From $110, Maintains Buy Rating. Oct. 20. Exact Sciences Corp. 65.13. Delayed Data. As of Nov 21. -2.15 / -3.20%. Today’s Change. 40.73. Today ||| 52-Week Range. 100.77.Cologuard uses a biomarker panel which analyzes a person’s stool sample for 10 DNA markers, as well as blood in the stool (hemoglobin). This multi-marker approach is a distinguishing feature of Exact Sciences’ scientific platform. Cologuard finds colon cancer even in early stages when it is more treatable. 1,2,3* Cologuard is convenient. Exact Sciences Corp. (Nasdaq: EXAS) (the "Company"), a leading provider of cancer screening and diagnostic tests, today announced that on February 23, 2023 it entered into a privately negotiated ...Ordinary share capital refers to shares that are issued by a company that allow shareholders voting rights within a corporation. Ordinary shareholders may also receive dividends. Ordinary shares are also referred to as common stocks.

Advertisement Exact Sciences Corporation (EXAS) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 65.27 +0.68 (+1.05%) At close: 04:00PM EDT 65.50 +0.23 (+0.35%) After...

View the latest Exact Sciences Corp. (EXAS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

EXAS is the ticker symbol for Exact Sciences Corporation, a company that provides cancer screening and diagnostic test products. The stock price, news, quote, history and performance outlook of EXAS are shown on Yahoo Finance. See the latest earnings report, analyst report, research reports and more. 04-Jan-2023 ... As illustrated in our open-source model, shares of Exact Sciences could compound at an average annual rate of 25%, reaching $140 by 2027.Get the latest stock price, quote, news and history of Exact Sciences Corporation Common Stock (EXAS), a biotechnology company that develops and …Exact Sciences Corporation completed the acquisition of Omicera Diagnostics Gmbh for $19.41 million on May 2, 2022. As part of the acquisition, Exact Sciences issued 265,186 common shares, contingent consideration of $4.6 million, Working capital adjustment to be settled in cash of $0.016 million and maximum of $6 million of additional cash ...Check out my recommendation on EXAS stock. Exact Sciences' successful BLUE-C study and potential FDA approval for the upgraded test may drive revenues. ... 2023 8:00 AM ET Exact Sciences ...Negative. Nikkei 225. 33,451.83. +0.29%. Positive. Source: LSEG - data delayed by at least 15 minutes. Get Exact Sciences Corp (EXAS.A) real-time stock quotes, news, price and financial ...Exact Sciences Corporation is a global advanced cancer diagnostics company. The Company provides a portfolio of products for earlier cancer detection and ...Exact Sciences Corporation. 21 Feb, 2023, 16:05 ET. Reports record revenue, expects revenue of $2,265 -2,315 million and positive adjusted EBITDA for full year 2023. Fourth quarter and 2022 ...

15-May-2017 ... One week after hitting an all-time high, Exact Sciences Corp. stock slipped as much as 8 percent in early trading Monday after a well-known ...EXACT Sciences Corporation stock performance at a glance. Check EXACT Sciences Corporation’s past financial performance, like revenue or net income, plus the top level …June 7, 2023 at 10:53 AM · 4 min read. Exact Sciences Corporation EXAS is well poised for growth in coming quarters, led by the continued strength across the Screening and Precision Oncology ...Instagram:https://instagram. best bank dividend stocksbest trading software for pcsevcq stocknasdaq exel Nov 30, 2023 · Stock analysis for Exact Sciences Corp (EXAS:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. The Exact Sciences Corp (NASDAQ: EXAS) stock price reached the ceiling this week, with shares gaining a sizable 16.38% over the past five days. Most of that value climb came yesterday, with the ... thinkorswim newsbest investment loan lenders The company's screening revenue (including laboratory services for Cologuard) saw an even more significant growth of 45% year over year. While Exact Sciences remains unprofitable, there was major ... best desktop trading platform Exact Sciences' revenue has grown rapidly in the past five years, but the bottom line hasn't made much progress. Cologuard 2.0 should help the company's top line maintain its momentum. Exact ...22-Feb-2022 ... MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that ...